PLoS ONE · 2022 · 34 citations · 19 references
ImmunodeficienciesImmunologyCox RegressionVaccine HesitancyCovid-19Preventive MedicinePost-infection ImmunityVaccine SurveillanceVaccine EffectivenessInfection ControlPrevious InfectionVaccinologyVaccine SafetyCovid-19 InfectionVaccine DevelopmentMedicineCovid-19 PandemicVaccine TestingBooster DosesEpidemiologyVaccinationVaccine EfficacyPrecision VaccinologyVaccine Research
Studies demonstrating the waning of post-vaccination and post-infection immunity against covid-19 generally analyzed a limited range of vaccines or subsets of populations. Using Czech national health data from the beginning of the covid-19 pandemic till November 20, 2021 we estimated the risks of reinfection, breakthrough infection, hospitalization and death by a Cox regression adjusted for sex, age, vaccine type and vaccination status. Vaccine effectiveness against infection declined from 87% at 0-2 months after the second dose to 53% at 7-8 months for BNT162b2 vaccine, from 90% at 0-2 months to 65% at 7-8 months for mRNA-1273, and from 83% at 0-2 months to 55% at 5-6 months for the ChAdOx1-S. Effectiveness against hospitalization and deaths declined by about 15% and 10%, respectively, during the first 6-8 months. Boosters (third dose) returned the protection to the levels observed shortly after dose 2. In unvaccinated, previously infected individuals the protection against infection declined from 97% after 2 months to 72% at 18 months. Our results confirm the waning of vaccination-induced immunity against infection and a smaller decline in the protection against hospitalization and death. Boosting restores the original vaccine effectiveness. Post-infection immunity also decreases over time.
19
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin et al. · New England Journal of Medicine · 2020 · 15.1K citations · Full text
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
New England Journal of Medicine · 2020 · 10.4K citations · Full text
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower et al. · New England Journal of Medicine · 2021 · 3.1K citations · Full text
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Jerald Sadoff, Glenda Gray, An Vandebosch et al. · New England Journal of Medicine · 2021 · 2.5K citations · Full text